This is the first in a three-part series putting real numbers behind the make-versus-buy question for experiment-ready virus. Each post walks through one representative project — how much virus it takes, and what that volume actually costs to produce in-house versus buy. We start with the simplest case: validating a plaque assay.
How Much Virus This Project Needs
Influenza A (Orthomyxoviridae) is a BSL-2 virus with moderate titers (– TCID50/mL or PFU/mL) — plenty for standard in vitro work. A plaque assay / TCID50 titration, run as a full dilution series in triplicate, typically consumes only about 1.0–5.0 mL of virus. That’s the volume this project is built around.
Why Fixed Costs Dominate Small Projects
Whether a lab needs 2.0 mL or 50.0 mL, most of the same steps must happen: cell culture expansion, virus amplification, titer determination, sterility and QC testing, genetic confirmation, documentation, and aliquot/storage validation. None of those scale down with volume, which is why small projects carry the highest cost per milliliter when made in-house.
The Actual Numbers
Buying several experiment-ready aliquots for this project typically costs $2,000–4,000, and experiments can start immediately.
To produce the same 2.0 mL internally, fully burdened organizational costs rather than just incremental laboratory consumable costs can run to $50,000–90,000 once scientist time, facility operation, QC, and documentation are included. Because those costs barely change with volume, buying is more than 20 times cheaper for a project this size.
|
Project |
Virus Needed |
Est. Commercial Purchase* |
Est. Fully Burdened In-House Production** |
|
Influenza plaque assay validation |
~1.0-5.0 mL |
$2,000–6,000 |
$50,000–90,000 |
What This Means for Planning
For small, one-off validation work, buying isn’t a close call — a handful of aliquots gets you into the assay in days instead of months. The calculus shifts at higher containment levels and larger volumes, which is where the rest of this series goes next.
Up next: Part 2 looks at a SARS-CoV-2 neutralization study — where containment pushes the in-house price tag even higher.
Advanced Virology: Numbers You Can Plan Around
At Advanced Virology Inc., we help labs size experiment-ready volumes to the actual project — including small validation studies like this one — so teams get exactly what they need without absorbing the fixed costs of standing up production themselves.
Ready to explore how standardized virus stocks can accelerate your research? Get in touch to discuss your specific volume and timeline.
*Commercial pricing is representative and varies based on virus, biosafety level, characterization requirements, order size, product grade, and supplier.
**Estimated in-house costs include personnel, facilities, consumables, quality control, sequencing, documentation, equipment depreciation, and opportunity costs. Actual costs vary by institution. In-house estimates represent fully burdened organizational cost. Incremental laboratory costs alone can be substantially lower but do not capture personnel allocation, facility utilization, quality systems, equipment depreciation, or project delays.